Societe des Industries Pharmaceutiques de Tunisie SA
BBVMT:SIPHA3.55
TND
-0.42
(-10.58%)
Societe des Industries Pharmaceutiques de Tunisie SA
BVMT:SIPHA
(Tunis Stock Exchange)
Recent
price
3.55
P/E
ratio
- -
div
yld
- -
ROIC.AI
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Semi-annual Revenue
FRC
•
in mil. unless spec.Semi-annual Earnings Per Share
FRC
•
in mil. unless spec.Semi-annual Dividends Per Share
FRC
•
in mil. unless spec.- Similar Companies
- Business
- Societe des Industries Pharmaceutiques de Tunisie SA is a Tunisia-based pharmaceutical manufacturing company engaged in the research, development, production, packaging, and commercialization of generic and branded medicines for human healthcare. Founded in 1989 and headquartered in Ben Arous, Tunisia, the company operates as a publicly listed entity majority-owned by the Pharmacie Centrale de Tunisie. The company's core product portfolio spans diverse dosage forms and therapeutic classes, comprising sterile injectable preparations, including intravenous infusion bags, physiological saline solutions, and glucose serums; solid oral dosage forms, including generic and proprietary tablets, capsules, and coated caplets; liquid oral formulations, including medicinal syrups, oral suspensions, pediatric remedies, and antacids; semi-solid and pasty formulations, including dermatological ointments, topical creams, and suppositories; anti-infective and antibiotic medications; analgesics and antipyretics; gastrointestinal and metabolic treatments; cardiovascular therapies; and central nervous system medications. Additionally, the company provides industrial toll manufacturing, licensed pharmaceutical production, packaging services, and analytical quality control testing for domestic and multinational pharmaceutical partners. The company primarily serves the national public hospital network and retail pharmacy dispensaries in Tunisia, while maintaining selective export channels across the Middle East and Africa. In recent operational developments, the company has engaged in an extensive state-backed industrial rehabilitation program to restore production capacity across several previously idled manufacturing units, successfully reactivating production lines for sterile saline solutions, suppository workshops, solid dry forms, and liquid syrup formulations. To improve long-term solvency and operational efficiency, the company is advancing a comprehensive financial and operational restructuring plan aimed at stabilizing institutional debt, modernizing facility infrastructure, digitalizing production tracking, and securing the domestic supply of essential pharmaceuticals.